☆ 4.7 Article

Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2

ANNALS OF THE RHEUMATIC DISEASES (2021)

期刊

ANNALS OF THE RHEUMATIC DISEASES

卷 80, 期 10, 页码 1317-1321

出版社

BMJ PUBLISHING GROUP

DOI: 10.1136/annrheumdis-2021-220503

关键词

类别

Rheumatology

向作者/读者索取更多资源

Protocol

社区支持

Reagent

社区支持

智能总结 New
摘要

The vast majority of patients with inflammatory rheumatic diseases developed a significant humoral response following the administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2 virus. Only minor side effects were reported and no apparent impact on IRD activity was noted.

Background The registration trials of messenger RNA (mRNA) vaccines against SARS-CoV-2 did not address patients with inflammatory rheumatic diseases (IRD). Objective To assess the humoral response after two doses of mRNA vaccine against SARS-CoV-2, in patients with IRD treated with immunomodulating drugs and the impact on IRD activity. Methods Consecutive patients treated at the rheumatology institute, who received their first SARS-CoV-2 (Pfizer) vaccine, were recruited to the study, at their routine visit. They were reassessed 4-6 weeks after receiving the second dose of vaccine, and blood samples were obtained for serology. IRD activity assessment and the vaccine side effects were documented during both visits. IgG antibodies (Abs) against SARS-CoV-2 were detected using the SARS-CoV-2 IgG II Quant (Abbott) assay. Results Two hundred and sixty-four patients with stable disease, (mean(SD) age 57.6 (13.18) years, disease duration 11.06 (7.42) years), were recruited. The immunomodulatory therapy was not modified before or after the vaccination. After the second vaccination, 227 patients (86%) mounted IgG Ab against SARS-CoV-2 (mean (SD) 5830.8 (8937) AU/mL) and 37 patients (14%) did not, 22/37 were treated with B cell-depleting agents. The reported side effects of the vaccine were minor. The rheumatic disease remained stable in all patients. Conclusions The vast majority of patients with IRD developed a significant humoral response following the administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2 virus. Only minor side effects were reported and no apparent impact on IRD activity was noted.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

主要评分

4.7

评分不足

次要评分

新颖性

重要性

科学严谨性

评价这篇论文

Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases

Catherine E. Raptis, Christoph T. Berger, Adrian Ciurea, Diego O. Andrey, Christos Polysopoulos, Pierre Lescuyer, Tanja Maletic, Myriam Riek, Almut Scherer, Isabell von Loga, Judith Safford, Kim Lauper, Burkhard Moller, Nicolas Vuilleumier, Axel Finckh, Andrea Rubbert-Roth

Summary: This study aimed to compare the humoral immunogenicity following BNT162b2 and mRNA-1273 vaccination in patients with inflammatory rheumatic diseases (IRD). The results showed that two-dose vaccination with mRNA-1273 resulted in higher antibody levels compared to BNT162b2 in IRD patients, especially in elderly patients.

FRONTIERS IN IMMUNOLOGY (2022)